- Home
- SJT vs IPHA Comparison
SJT vs IPHA Comparison
Compare SJT & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJT
- IPHA
- Stock Information
- Founded
- SJT 1980
- IPHA 1999
- Country
- SJT United States
- IPHA France
- Employees
- SJT N/A
- IPHA N/A
- Industry
- SJT Oil & Gas Production
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- SJT Energy
- IPHA Health Care
- Exchange
- SJT Nasdaq
- IPHA Nasdaq
- Market Cap
- SJT 212.1M
- IPHA 150.9M
- IPO Year
- SJT N/A
- IPHA 2019
- Fundamental
- Price
- SJT $4.06
- IPHA $1.95
- Analyst Decision
- SJT
- IPHA Strong Buy
- Analyst Count
- SJT 0
- IPHA 1
- Target Price
- SJT N/A
- IPHA $11.50
- AVG Volume (30 Days)
- SJT 230.2K
- IPHA 50.9K
- Earning Date
- SJT 11-14-2024
- IPHA 03-20-2025
- Dividend Yield
- SJT 2.33%
- IPHA N/A
- EPS Growth
- SJT N/A
- IPHA N/A
- EPS
- SJT 0.19
- IPHA N/A
- Revenue
- SJT $11,031,594.00
- IPHA $36,202,722.00
- Revenue This Year
- SJT N/A
- IPHA N/A
- Revenue Next Year
- SJT N/A
- IPHA $101.65
- P/E Ratio
- SJT $21.16
- IPHA N/A
- Revenue Growth
- SJT N/A
- IPHA N/A
- 52 Week Low
- SJT $3.21
- IPHA $1.29
- 52 Week High
- SJT $5.81
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- SJT 42.74
- IPHA 56.50
- Support Level
- SJT $4.12
- IPHA $1.72
- Resistance Level
- SJT $4.30
- IPHA $1.92
- Average True Range (ATR)
- SJT 0.19
- IPHA 0.11
- MACD
- SJT -0.04
- IPHA 0.02
- Stochastic Oscillator
- SJT 1.28
- IPHA 89.74
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.